Company Overview

Aclarion, Inc. is a healthcare technology company focused on advancing precision medicine in the treatment of chronic low back pain. The company operates at the intersection of medical imaging, artificial intelligence, and spine care, developing tools designed to help physicians identify the specific pain-generating source in patients with chronic low back pain. Aclarion’s primary product platform, NOCISCAN, is a software-based diagnostic aid that analyzes magnetic resonance imaging (MRI) data using proprietary algorithms to identify biomarkers associated with discogenic pain.

Founded in 2017, Aclarion was established to address the high clinical and economic burden of nonspecific low back pain, an area where conventional imaging often fails to correlate anatomy with pain symptoms. The company has positioned itself as a clinical decision-support provider rather than a device manufacturer, emphasizing data-driven insights to improve surgical decision-making, reduce unnecessary procedures, and improve patient outcomes.

Business Operations

Aclarion generates revenue primarily through the commercialization and clinical deployment of its NOCISCAN platform, which is offered to spine surgeons, interventional pain specialists, and healthcare systems. The platform is designed to integrate with existing MRI infrastructure, allowing imaging centers and hospitals to upload scan data for algorithmic analysis without the need for new hardware. Revenue is primarily derived from per-scan usage fees and clinical access agreements.

The company’s operations are predominantly domestic, with commercial and clinical activities centered in the United States. Aclarion maintains control over its core intellectual property, including proprietary imaging biomarkers and analytics software, and collaborates with academic medical centers and spine care providers for clinical validation and adoption. Public disclosures indicate no material subsidiaries or joint ventures, with operations conducted directly through the parent company.

Strategic Position & Investments

Aclarion’s strategic focus is on expanding clinical adoption of NOCISCAN by building clinical evidence, securing reimbursement pathways, and integrating its technology into standard spine care workflows. Growth initiatives emphasize prospective clinical studies, physician education, and partnerships with leading spine centers to validate real-world utility. The company has also focused on aligning its platform with value-based care models by demonstrating potential reductions in unnecessary spinal surgeries.

The company has not disclosed major acquisitions and appears to pursue organic growth rather than expansion through mergers. Its investments are primarily directed toward software development, data science, regulatory compliance, and clinical research. Aclarion remains focused on emerging applications of artificial intelligence in diagnostic imaging, particularly in musculoskeletal and spine-related conditions.

Geographic Footprint

Aclarion is headquartered in Austin, Texas, and its operational footprint is primarily concentrated in North America. The company’s commercial activities, clinical partnerships, and regulatory strategy are largely focused on the United States, reflecting its emphasis on U.S. spine care markets and reimbursement systems.

While Aclarion has indicated that its technology is scalable for international use, public disclosures show limited direct operational presence outside the United States. Any international exposure to date appears to be exploratory or research-oriented rather than indicative of established overseas operations.

Leadership & Governance

Aclarion is led by a management team with experience in healthcare technology, medical imaging, and commercial-stage life sciences. The leadership emphasizes clinical validation, physician engagement, and disciplined capital allocation as core elements of its strategic vision, with a stated focus on improving diagnostic accuracy and patient outcomes in spine care.

Key executives include:

• Brandon S. Smith – Chief Executive Officer
• David S. Hirsch – Chief Financial Officer
• Narbeh Melikian, PhD – Chief Technology Officer
• Dr. Tony Boutin – Chief Medical Officer

The company is governed by a board of directors that includes executives and independent directors with backgrounds in healthcare innovation, medical devices, and public company governance.